XMRV and Prostate Cancer: a final perspective

Karen Sfanos, Amanda Aloia, Angelo De Marzo, Alan Rein

    Research output: Contribution to journalReview articlepeer-review

    18 Citations (Scopus)


    XMRV was first described in 2006, when it was identified in samples isolated from prostate cancer tissues. However, studies have since shown that XMRV arose in the laboratory and was formed by genetic recombination between two viral genomes carried in the germline DNA of mice used during serial transplantation of the CWR22 prostate cancer xenograft. These new findings strongly imply that XMRV does not circulate in humans, but is only present in the laboratory. Thus, there is no reason to believe that it has any role in the etiology of prostate cancer or other diseases.

    Original languageEnglish
    Pages (from-to)111-118
    Number of pages8
    JournalNature Reviews. Urology
    Issue number2
    Publication statusPublished - Feb 2012


    Dive into the research topics of 'XMRV and Prostate Cancer: a final perspective'. Together they form a unique fingerprint.

    Cite this